Immunotoxin in Treating Patients With Leukemia or Lymphoma

DISEASE CHARACTERISTICS:

* Histologically confirmed Hodgkin's disease, non-Hodgkin's lymphoma, or leukemia in one of the following categories:

  * Adult T-cell leukemia or lymphoma (ATL)

    * No smoldering ATL
    * No limitation on prior therapy
  * Cutaneous T-cell lymphoma (CTCL)

    * Stages IB-III and failed at least 1 standard therapy
    * Stage IV regardless of prior therapy
  * Stages I-IV peripheral T-cell lymphoma

    * Relapsed after standard chemotherapy
    * Ineligible for or refused salvage chemotherapy or bone marrow transplantation (BMT)
  * B-cell non-Hodgkin's lymphoma (NHL) of any histology

    * Indolent stages II-IV NHL

      * Failed at least 1 standard therapy
      * Disease symptomatic and requiring treatment
    * Aggressive NHL

      * Relapsed after standard chemotherapy
      * Ineligible for or refused salvage chemotherapy or BMT
  * Chronic lymphocytic leukemia (CLL)

    * Rai stages III and IV or Binet stage C
    * Failed standard therapy and at least 1 salvage chemotherapy
  * Primary B-cell prolymphocytic leukemia or prolymphocytic transformation of CLL

    * Failed standard therapy and at least 1 salvage chemotherapy
  * Hairy cell leukemia

    * Failed standard and salvage chemotherapy
    * Ineligible for or refused further salvage chemotherapy or BMT
  * Acute myelogenous leukemia

    * Failed standard chemotherapy
    * Ineligible for or refused salvage chemotherapy or BMT
  * Stages II-IV Hodgkin's disease

    * Failed standard chemotherapy
    * Ineligible for curative salvage radiotherapy or chemotherapy
    * Ineligible for or refused BMT
  * Patients with leukemias or lymphomas not easily classified in above categories who have failed standard therapy and are ineligible for or have refused bone marrow transplant
* Evidence of interleukin-2 receptor-alpha (IL2Ra) expression by one of the following:

  * Greater than 10% of malignant cells reactive with anti-Tac by immunohistochemistry
  * Greater than 10% of malignant cells from a particular site positive by FACS
  * Greater than 400 IL2Ra sites per malignant cell by radiolabeled anti-Tac binding
  * Soluble IL2Ra level greater than 1,000 U/mL (normal geometric mean 235, with 95% confidence levels of 112-502 U)
  * Hodgkin's disease with measurable disease not amenable to biopsy
* No CNS disease requiring treatment

  * Malignant cells in CSF allowed if judged not to represent clinically significant leukemic or lymphomatous meningitis (as in CSF contamination by blood)

PATIENT CHARACTERISTICS:

Age:

* 18 and over

Performance status:

* Karnofsky 50-100%

Life expectancy:

* Greater than 2 months

Hematopoietic:

* Absolute neutrophil count greater than 1,000/mm3\*
* Platelet count greater than 50,000/mm3\* NOTE: \*nonleukemic patients

Hepatic:

* AST and ALT less than 5 times normal

Renal:

* Creatinine less than 2.0 mg/dL OR
* Creatinine clearance greater than 50 mL/min

Pulmonary:

* FEV1, TLC, and DLCO greater than 50% of predicted if pulmonary or mediastinal involvement with tumor greater than one third of total thoracic diameter

Other:

* HIV negative
* Not pregnant
* Fertile patients must use effective contraception
* Serum must neutralize no more than 75% LMB-2 in tissue culture

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* See Disease Characteristics
* At least 3 weeks since prior interferon

Chemotherapy:

* See Disease Characteristics
* At least 3 weeks since prior cytotoxic chemotherapy
* At least 3 weeks since prior retinoids
* No concurrent chemotherapy

Endocrine therapy:

* No concurrent corticosteroids unless begun at least 3 weeks prior to entry and dose not increased during 3 weeks prior to entry

Radiotherapy:

* See Disease Characteristics
* At least 3 weeks since prior whole-body electron beam radiotherapy
* Other radiotherapy allowed within 3 weeks of entry provided less than 10% of marrow irradiated and measurable disease exists outside radiation port

Surgery:

* Not specified

Other:

* See Disease Characteristics
* At least 3 weeks since any prior systemic therapy
* No other concurrent investigational agents